689
Participants
Start Date
August 31, 2011
Primary Completion Date
June 30, 2013
Study Completion Date
February 28, 2014
Placebo Q2W
Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
Tralokinumab 300 mg, Q2W
Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.
Placebo, Q2/4W
Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
Tralokinumab 300 mg, Q2/4W
Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
Research Site, Rancho Mirage
Research Site, Centennial
Research Site, New Haven
Research Site, Cocoa
Research Site, Miami
Research Site, Winter Park
Research Site, Albany
Research Site, Fargo
Research Site, Philadelphia
Research Site, Upland
Research Site, Killeen
Research Site, Buenos Aires
Research Site, Ciudad de Buenos Aires
Research Site, Monte Grande
Research Site, Ranelagh
Research Site, Rosario
Research Site, Calgary
Research Site, Ottawa
Research Site, Montreal
Research Site, Québec
Research Site, Quillota
Research Site, Santiago
Research Site, Valparaíso
Research Site, Viña del Mar
Research Site, Jindřichův Hradec
Research Site, Pilsen
Research Site, Rokycany
Research Site, Marseille
Research Site, Montpellier
Research Site, Nantes
Research Site, Paris
Research Site, Perpignan
Research Site, Pessac
Research Site, Strasbourg
Research Site, Berlin
Research Site, Frankfurt
Research Site, Lübeck
Research Site, Mainz
Research Site, Chūōku
Research Site, Fujisawa-shi
Research Site, Fukuoka
Research Site, Habikino-shi
Research Site, Hiroshima
Research Site, Itabashi-ku
Research Site, Kagoshima
Research Site, Kahoku-gun
Research Site, Kishiwada-shi
Research Site, Kobe
Research Site, Kyoto
Research Site, Maebashi
Research Site, Morioka
Research Site, Naka-gun
Research Site, Sagamihara-shi
Research Site, Sakaide-shi
Research Site, Sapporo
Research Site, Sumida-ku
Research Site, Takatsuki-shi
Research Site, Tomakomai-shi
Research Site, Wakayama
Research Site, Yokohama
Research Site, Culiacán
Research Site, Guadalajara
Research Site, México
Research Site, Morelia
Research Site, Querétaro City
Research Site, Tampico
Research Site, Villahermosa
Research Site, Iloilo City
Research Site, Lipa City
Research Site, Quezon City
Research Site, Lodz
Research Site, Wroclaw
Research Site, Zabrze
Research Site, Moscow
Research Site, Novosibirsk
Research Site, Saint Petersburg
Research Site, Vladikavkaz
Research Site, Yekaterinburg
Research Site, Bucheon-si
Research Site, Incheon
Research Site, Seoul
Research Site, Suwon
Research Site, Barcelona
Research Site, Madrid
Research Site, Pamplona
Research Site, Sagunto(Valencia)
Research Site, Santander
Research Site, Leicester
Research Site, Manchester
Lead Sponsor
MedImmune LLC
INDUSTRY